Biological Trace Element Research

, Volume 56, Issue 3, pp 331–341 | Cite as

The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients

  • Ya-Jun Hu
  • Yan Chen
  • Yong-Qiang Zhang
  • Mei-Zhen Zhou
  • Xue-Mei Song
  • Bao-Zhu Zhang
  • Ling Luo
  • Pei-Min Xu
  • Yi-Niam Zhao
  • Yun-Bo Zhao
  • Gang Cheng
Original Articles


The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 400 μg per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4±22.86 to 157.04±60.23 ng/mL (P<0.001) in patients received Se. The cisplatin dosage was iv administration in 60–80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35±2.01 vs 2.31±1.38 [×109L])/L,p<0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1±82.2 vs 723.6±192.6 IU,p<0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62±38mL,p<0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin.

Index Entries

Selenium (Seleno-Kappacarrageenan) Cisplatin toxicity (nephrotoxicity, bone marrow suppression), cancer patients 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. W. Prestayko, S. T. Crooke, and S. K. Carter, eds.Cis-platin: Current Status and New Developments. Academic, New York (1980).Google Scholar
  2. 2.
    T. P. Luckey and B. Wenugopol,Metal Toxicity in Mammals, vol. 2. Elsevier/North-Holland, Amsterdam (1977).Google Scholar
  3. 3.
    I. H. Krakoff, Nephrotoxicity of cis-dichlorodiammineplatinum (II),Cancer Treat. Rep. 63, 1523–1525 (1979).PubMedGoogle Scholar
  4. 4.
    E. M. Walker and G. R. Gale, Methods of reduction of cis-platin nephrotoxicity,Ann. Clin. Lab. Sci. 11, 397–410 (1981).PubMedGoogle Scholar
  5. 5.
    W. C. Rose and J. E. Schurig, Preclinical antitumor and toxicological profile of carboplatin,Cancer. Treat. Rep. 12 (suppl. A), 1–9 (1985).CrossRefGoogle Scholar
  6. 6.
    R. F. Ozols, B. J. Cordon, J. Jacob, M. N. Wesley, Y. Ostehega, and R. C. Young, High-dose cis-platin in hypertonic saline,Ann. Inter. Med. 100, 19–24 (1984).Google Scholar
  7. 7.
    C. E. Pfeifle, S. B. Howell, R. D. Felthouse, T. B. Woliver, P. A. Andrews, M. Markman, and M. P. Murphy, High dose-cis-platin with sodium thiosulfate protection,J. Clin. Oncol. 3, 237–244 (1987).Google Scholar
  8. 8.
    D. L. Bodenner, P. C. Dedon, J. C. Katz, and R. F. Borch, Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate,Cancer. Res. 46, 2751–2755 (1986).PubMedGoogle Scholar
  9. 9.
    M. L. Rothenberg, Y. Ostchega, S. M. Steinberg, R. C. Young, S. Hummel, and R. F. Ozols, High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer,J. Natl. Cancer Inst. 80, 1488–1492 (1988).PubMedCrossRefGoogle Scholar
  10. 10.
    M. Satoh, A. Naganuma, N. Imura. Deficiency of selenium intake enhances manifestation of renal toxicity of cis-diamminedichloroplatinum in mice,Toxicol. Lett. 38(1–2), 155–160 (1987).PubMedGoogle Scholar
  11. 11.
    L. N. Vernie, J. J. de-Goeij, C. Zeger, M. Devries, G. S. Baldew, and J. G. Mevie. Cisplatin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients,Cancer. lett 40(1), 83–91 (1988).PubMedCrossRefGoogle Scholar
  12. 12.
    V. R. Young, Selenium: a case for its essentiality in man,N. Engl. J. Med. 304, 1228 (1981).PubMedCrossRefGoogle Scholar
  13. 13.
    R. J. Shamberger and D. V. Frost, Possible protective effect of selenium against human cancer,Can. Med. Ass. J. 103, 682 (1969).Google Scholar
  14. 14.
    Y. J. Chu, Q. Y. Liu, C. Hou, and S. Y. Yu, Blood selenium concentration in residents of areas in China having a high incidence of lung cancer,Biol Trace Element Res. 6(2), 133–137 (1984).Google Scholar
  15. 15.
    W. Willett, B. F. Polk, S. Morris, M. J. Stampfer, S. Pressel, B. Rosnern, J. O. Taylor, K. Schneider, and C. G. Hames, Prediagnostic serum selenium and risk of cancer,Lancet 2, 130–134 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    P. Knekt, A. Aromaa, L. Maateta, et al. Serum selenium and subsequent risk of cancer among Finnish men and woman.J. Nat. Cancer. Inst. 82(10), 846–848 (1990).CrossRefGoogle Scholar
  17. 17.
    K. P. McConnell, W. L. Broghamer, A. J. Blotcky, Selenium levels in human blood and tissue in health and disease,J. Nutr. 105, 1026–1031 (1975).PubMedGoogle Scholar
  18. 18.
    Y. J. Hu, Y. N. Zhao, P. M. Xu, S. D. Yang, Y. W. Lin, and J. H. Wu, A study of blood selenium levels in patients with lung cancer and healthy subjects in Beijing area,Acta Nutrimenta. Sinica. 16(3), 261–264 (1994).Google Scholar
  19. 19.
    C. Ip. Factors influencing the anticarcinogenic efficacy of selenium in dimethylbenz (a)anthracene-induced mammary tumorigenesis in rats,Cancer Res. 41, 2683–2686 (1981).PubMedGoogle Scholar
  20. 20.
    C. Ip, M. M. Ip, and U. Kim, Dietary selenium intake and growth of MT-W9B transplantable rat mammary tumor,Cancer Lett. 14, 101–107 (1981).PubMedCrossRefGoogle Scholar
  21. 21.
    G. Hocman, Chemoprevention of cancer: selenium,Int. J. Biochem. 20(2), 123–132 (1988).PubMedCrossRefGoogle Scholar
  22. 22.
    A. M. Watrach, J. A. Milner, M. A. Watrach, and K. A. Poirier, Inhibition of human breast cancer cells by selenium,Cancer Lett 25(1), 41–47 (1984).PubMedCrossRefGoogle Scholar
  23. 23.
    S. Y. Yu, Y. J. Chu, W. G. Li, Q. S. Huang, C. Z. Huang, Q. N. Zhang, and C. Hou, A preliminary report on the intervention trials of primary liver cancer in high risk populations with nutritional supplementation of selenium in China,Biol. Trace Elements Res. 29, 289–294 (1991).CrossRefGoogle Scholar
  24. 24.
    W. L. Blot, J. Y. Li, P. R. Taylor, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population,J. Natl. Cancer. Inst. 85(18), 1483–1492 (1993).PubMedCrossRefGoogle Scholar
  25. 25.
    A. Naganuma, M. Satoh, M. Yokoyama, and N. Imura, Selenium efficiently depressed toxic side effect of cis-diamminedichloroplatinum,Res. Commun Chem. Pathol. Pharmacol. 42(1), 127–134 (1983).PubMedGoogle Scholar
  26. 26.
    J. P. Berry, C. Pauwells, S. Tlouzeau, and G. Lespinats, Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma,Cancer. Res. 44(7), 2864–2868 (1984).PubMedGoogle Scholar
  27. 27.
    M. Yokoyama, A. Naganuma and N. Imura, Suppression of CDDP-induced renal toxicity by sodium selenite,Gan. No. Rinsho. (Japanese)31(9 Suppl), 1225–1230 (1985).Google Scholar
  28. 28.
    K. Ohkawa, Y. Tsukada, and H. Dohzono, K. Koike, and Y. Terashima, The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity,Br. J. Cancer. 58(10) 38–41 (1988).PubMedGoogle Scholar
  29. 29.
    G. S. Baldew, C. J. Van-den Hamer, G. Los, N. P. E. Vermeulen, J. J. M. de Goeij, and J. G. Mevie, Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats,Cancer. Res. 49(11), 3020–3023 (1989).PubMedGoogle Scholar
  30. 30.
    G. S. Baldew, J. G. McVie, M. A. Van-der-valk, G. Los, J. J. de Goeij, and N. P. E. Vermeulen, Selective reduction of cis-diammindichloroplatinum(II) nephrotoxicity by ebselen,Cancer. Res. 50(21), 7031–7036 (1990).PubMedGoogle Scholar
  31. 31.
    Y. Araya, Studies on protective effect of selenium on the nephrotoxicity of cisdiamminedichloroplatinum (CDDP) in mice,Hokkaido. Igoaku. Zasshi. 65(3), 245–253 (1990).Google Scholar
  32. 32.
    M. Satoh, A. Naganuma, and N. Imura, Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum (cis-DDP) in mice,J. Pharmacobiodyn. 12(4), 246–253 (1989).PubMedGoogle Scholar
  33. 33.
    B. Leyland Jones, C. Morrow, S. Tate, C. Urmacher, C. Gordon, and C. W. Young, Cisdiamminedichloroplatinum(II) nephrotoxicity and Its relationship to renal to gammaglutamyl transpeptidase and glutathione,Cancer. Res,43(12 pt 1), 6072–6076 (1983).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1997

Authors and Affiliations

  • Ya-Jun Hu
    • 1
  • Yan Chen
    • 1
  • Yong-Qiang Zhang
    • 1
  • Mei-Zhen Zhou
    • 1
  • Xue-Mei Song
    • 3
  • Bao-Zhu Zhang
    • 1
  • Ling Luo
    • 2
  • Pei-Min Xu
    • 1
  • Yi-Niam Zhao
    • 1
  • Yun-Bo Zhao
    • 1
  • Gang Cheng
    • 1
  1. 1.Department of Medical OncologyBeijing HospitalP.R. China
  2. 2.Department of BiochemistryBeijing HospitalP.R. China
  3. 3.Beijing Tian Ci Fu Medical Biology CompanyP.R. China

Personalised recommendations